Case Studies on Regulatory Acceptance of Virtual Site Visits in Clinical Trials

Introduction: Regulatory Shift Toward Virtual Oversight

The evolution of decentralized clinical trials has propelled virtual site visits from an emergency workaround during the COVID-19 pandemic to a long-term solution for remote oversight. However, regulatory acceptability of such visits depends on strict adherence to Good Clinical Practice (GCP), documented procedures, and quality systems supporting remote operations.

Regulators including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan’s PMDA have provided guidance, but expect sponsors to demonstrate control and data integrity when using remote visit modalities. This article explores case studies where regulatory acceptability was achieved—or challenged—due to virtual site visit practices.

Case Study 1: EMA Inspection of a Cardiovascular Study Using Hybrid Visits

Background: A sponsor conducted a hybrid model of monitoring in a Phase III cardiovascular trial, with 50% of visits conducted remotely. The sponsor used a validated version of Microsoft Teams integrated with Veeva Vault eTMF for documentation.

Inspection Observations: The EMA requested access to monitoring visit reports, screen-sharing logs, and SOPs describing the hybrid visit workflow. The sponsor presented a virtual visit checklist, delegation logs, and a CAPA record for a previously identified access failure incident.

Outcome: The EMA accepted the virtual visit model, citing the sponsor’s strong documentation, pre-defined SOPs, and transparent CAPA process. No critical observations were issued.

Case Study 2: FDA Form 483 Issued for Poor Audit Trail in Remote Review

Background: A sponsor in an oncology trial conducted all monitoring visits virtually using a non-validated commercial video platform without clear audit trails or pre-approved procedures.

Inspection Findings: During a routine BIMO (Bioresearch Monitoring Program) inspection, the FDA noted lack of system validation, undocumented screen-sharing sessions, and missing logs for source document review.

Outcome: A Form 483 was issued for inadequate monitoring practices. The FDA recommended formal validation of the chosen platform, proper training logs, and maintenance of session audit trails.

CAPA Response: The sponsor transitioned to a compliant system, implemented SOPs, and trained all CRAs and sites on revised virtual monitoring practices.

Case Study 3: PMDA Acceptance of Remote Visits in a Rare Disease Trial

Background: A Japanese site in a rare disease trial received all monitoring visits virtually during national lockdowns. The sponsor documented visit objectives, access permissions, and eTMF uploads systematically.

Regulatory Response: During inspection, PMDA reviewed remote visit reports, session logs, and system access controls. They noted no deviations, and found evidence of thorough CRA review and site response documentation.

Outcome: PMDA accepted the remote monitoring approach, indicating that regulatory expectations were met through structured processes and validated tools.

Comparative Table of Case Outcomes

Lessons Learned from Regulatory Feedback on Virtual Visits

Regulatory agencies do not reject virtual site visits outright. Instead, they evaluate the robustness of processes that support these visits. The following are key lessons learned:

• Validation Is Non-Negotiable: Any tool used for source review or document sharing must be Part 11 or Annex 11 compliant, and validated for intended use.
• SOPs Drive Acceptability: Clearly defined SOPs outlining the steps, roles, documentation, and CAPA for virtual visits are essential.
• Audit Trails Are Critical: If it’s not documented, it didn’t happen. Agencies want to see session logs, timestamps, and document versions.
• CAPA Records Show Maturity: When issues arise (as they often do with tech), sponsors are expected to identify root cause and document resolution pathways.
• eTMF Integration Matters: Uploading signed reports, annotated screenshots, and CRA notes into the eTMF makes inspection readiness achievable.

Regulatory Reference Example

For further guidance on regulatory expectations around virtual monitoring, refer to:

EU Clinical Trials Register – EMA Monitoring Guidance

CAPA Framework for Virtual Visit Issues

When regulators identify gaps in virtual visit execution, a CAPA framework should include:

• Root cause analysis of failed visits (technical, procedural, human error).
• Training logs to address gaps in site or CRA understanding.
• Change control and updated SOPs if required.
• Verification steps (e.g., simulation visit or checklists).

Inspection-readiness teams should also review monitoring logs monthly to detect anomalies and preempt regulatory concern.

Conclusion: Meeting Regulatory Expectations through Preparedness

Virtual site visits can meet—and sometimes exceed—regulatory expectations if conducted within a robust quality framework. Documentation, validation, training, and traceability remain foundational pillars regardless of the format (remote or onsite). These case studies demonstrate that regulators accept remote models when quality, compliance, and transparency are prioritized.

Sponsors and CROs aiming for global trial execution must ensure their virtual oversight tools and practices align with current and emerging regulatory inspection trends.

How to Conduct Virtual Site Visits with a CAPA-Driven Approach

Introduction: Virtual Site Visits and Regulatory Expectations

The evolution of decentralized clinical trials and remote monitoring practices has brought virtual site visits to the forefront of regulatory oversight strategies. Both sponsors and clinical sites must now demonstrate compliance with Good Clinical Practice (GCP) while conducting remote visits that meet the expectations of authorities like the FDA, EMA, and ICH.

Unlike traditional on-site visits, virtual site visits introduce new challenges related to technology, security, documentation, and real-time communication. Consequently, implementing a Corrective and Preventive Action (CAPA) framework during these visits becomes essential to ensure issues are managed systematically and future risks are mitigated.

This tutorial outlines the key steps for conducting a virtual site visit using a structured CAPA framework and highlights regulatory expectations along with real-world examples.

Step-by-Step Process for Virtual Site Visits

Virtual site visits can be categorized into various types—site qualification, initiation, monitoring, and closeout. Regardless of visit type, a standardized process must be followed to ensure regulatory compliance and audit readiness. Below is a structured walkthrough of the process.

Step 1: Pre-Visit Planning and Risk Assessment

Pre-visit planning involves risk-based decision-making to identify which sites require virtual visits, the focus of the visit, and anticipated challenges. Sponsors typically develop a Virtual Site Visit Plan (VSVP) as a formal document.

Key Elements of the VSVP include:

• Purpose and scope of the visit
• Technology platforms to be used (e.g., Zoom, Microsoft Teams, Veeva)
• Roles and responsibilities
• Schedule of sessions with key personnel
• Data access permissions and audit trail enablement
• Confidentiality and security provisions

Use of remote monitoring platforms must comply with EU Clinical Trial Regulation 536/2014 and 21 CFR Part 11 standards for data integrity.

Step 2: Site Readiness and Pre-Qualification

Prior to the visit, the site must complete a Virtual Visit Readiness Checklist that includes:

• Hardware and internet speed checks
• Availability of staff and key personnel
• Testing of screen sharing and document access tools
• Confirmation of data de-identification (if applicable)
• Backup plan in case of connectivity failures

A dummy table of readiness status can be maintained:

Step 3: Conducting the Visit – Real-Time Execution

During the actual virtual site visit, the following activities must be documented:

• Review of regulatory documents (e.g., 1572, IRB approvals, CVs)
• Live review of electronic source documents (eSource)
• Verification of informed consent process
• Interviewing site staff regarding protocol adherence
• Observing drug storage areas via live video
• Monitoring AE/SAE documentation handling

The virtual visit should be recorded (if permitted), and notes must be entered into a Virtual Visit Log filed in the TMF.

Step 4: CAPA Identification During and After the Visit

Any deficiencies observed during the virtual site visit should be captured and evaluated through a CAPA process. CAPA identification must include:

• Clear description of issue (e.g., missing PI signature on lab report)
• Risk assessment (e.g., High – Subject Safety Impact)
• Root cause analysis (RCA) – using 5 Whys or Fishbone diagram
• Immediate correction (e.g., obtain signature, retrain staff)
• Preventive actions (e.g., system alerts, SOP revision)

Example CAPA record:

Step 5: Post-Visit Documentation and TMF Filing

All virtual visit documents must be archived appropriately in the TMF (Trial Master File). Key documents include:

• Virtual Site Visit Plan
• Readiness checklist and screenshots
• Virtual Site Visit Log
• CAPA tracking sheet
• Correspondence emails
• Audit trail exports

Filing should follow the DIA TMF Reference Model and be traceable for inspectors.

Best Practices and Common Pitfalls

Lessons learned from industry case studies reveal some best practices and pitfalls:

Best Practices:

• Conduct dry runs prior to scheduled visit
• Use dual monitors for simultaneous document review
• Assign a dedicated tech support liaison
• Log all time-stamped notes into the eTMF

Common Pitfalls:

• Relying on unsecured file-sharing platforms
• Failing to test video tools under firewall restrictions
• Skipping root cause analysis for minor issues
• Neglecting real-time documentation during the visit

Conclusion: Integrating CAPA into Virtual Oversight

Virtual site visits are no longer optional—they are a regulatory reality. However, their success hinges on a CAPA-driven framework that goes beyond operational execution. Sponsors must integrate proactive issue identification, structured correction, and long-term prevention into each virtual oversight activity.

By following the steps outlined in this guide, sponsors and CROs can improve both the effectiveness and defensibility of virtual site visits. More importantly, they can demonstrate to regulators that quality systems are evolving alongside technology.